RxDoctor Payments Data

Jinyan Zhang

Physician Assistant · Brooklyn, NYNPI 1801521802

Payments from drug & device makers

$2,070in general payments, 2019–2025

Across 46 payments — averaging $45.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$745
  • AbbVie$439
  • Intra-sana Laboratories$200
  • Amgen$182
  • Agios Pharmaceuticals, Inc.$73
  • Exact Sciences$70
  • plus $360 from 11 others

What the payments were for

  • Food & beverage$1,87090%
  • Gifts$20010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,070 in reported general payments places this provider in the 85th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$6,429
Medicare patients
41
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide35$48,098
VascepaIcosapent Ethyl78$32,262
CreonLipase/Protease/Amylase18$26,338
JardianceEmpagliflozin29$24,549
JanuviaSitagliptin Phosphate30$20,549
LinzessLinaclotide34$18,700
FarxigaDapagliflozin Propanediol15$9,523
EliquisApixaban13$7,362
Diclofenac Epolamine11$7,191
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag50$6,175
Omeprazole382$2,730
Dexlansoprazole DrDexlansoprazole15$2,435
Diclofenac Sodium13$2,052
Icosapent Ethyl13$1,917
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl120$1,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$745$48,09835 claims
AbbVieCreon, Linzess$439$45,03852 claims
MerckJanuvia$48$20,54930 claims
PfizerEliquis$18$7,36213 claims
Braintree Laboratories, Inc.Suflave$19$6,17550 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →